Brand Name: Therabloc

Generic Name: Hypertension, angina pectoris, acute MI

Indications: Hypertension; angina pectoris; MCI; PVC; unlabeled uses: prevention of migraine
headaches, management of tremors, alcohol withdrawal, and anxiety.
Drug Classification: Antihypertensive, Antianginal, Antiarryhthmic
Mechanism of Action: Block stimulation of beta1 (myocardial) adrenergic receptors. Do not usually
affect beta2 (pulmonary, vascular, uterine) receptor sites.
Therapeutic Effects: decreased blood pressure and heart rate, decreased frequency of attacks
of angina pectoris, slowing of ventricular response.
Dosage: PO (Adults):
Antianginal- 50 mg once daily initially, may be increased after 1 week to 100 mg/day may
then be increased as needed.
Antihypertensive- 25-50 mg once daily initially, may be increased after 2 wk to 50-100 mg
once daily.
MCI- 50 mg (given 10 min following last IV dose), then 50 mg 12 hr later, then 100 mg/day
as a single dose or in 2 divided doses for 6-9 days or until hospital discharge.
Special Precaution: Patients with renal impairment, hepatic impairment, pulmonary disease, diabetes
mellitus, thyrotoxicosis, with a history of severe allergic reactions, geriatric patients, pregnant
and lactating women
Pregnancy Risk Category: B
Adverse Reaction:
CNS: fatigue, weakness, dizziness, depression, insomnia, memory loss, mental stats changes,
nightmares, anxiety, nervousness, drowsiness.
EENT: blurred vision, stuffy nose.
Resp: bronchospasm, wheezing.
CV: bradycardia, congestive heart failure, pulmonary edema, peripheral vasoconstriction,
hypotension.
GI: constipation, diarrhea, nausea, vomiting, liver function abnormalities.
GU: impotence, decreased libido, urinary frequency.
Derm: rashes
Endo: hyperglycemia, hypoglycemia
MS: joint pain, back pain, arthralgia
Contraindications: Uncompensated congestive heart failure, pulmonary edema, cardiogenic shock,
bradycardia of heart block
Form:
Tablets: 25 mg, 50 mg, 100 mg, Injection: 500 mcg
Nursing Responsibilities:
 Monitor vital signs and ECG should be monitored q 5-15 min during and for several hours
after parenteral administration.
 Administer atropine if heart rate is <40 bpm, especially if cardiac output is decreased.
 Monitor intake and output ratios and daily weights.
 Assess routinely for signs and symptoms of CHF.